International Symposium ACUTE LEUKEMIAS XVIII (ISALXVIII) - Biology and Treatment Stragegies
ORGANIZING OFFICE: Beate Buske-Kosel, M.A.
It is our great pleasure to invite you to participate in the first hybrid ISAL symposium on ACUTE LEUKEMIAS (ISALXVIII) held in Munich, February 20-23, 2022. While we are optimistic about the recent developments in fighting the pandemic, which will hopefully enable a high level of on-site participation, we are taking into account the current developments and want to be prepared on any changes. We are therefore pleased to inform you that the symposium will be continuing forward as a hybrid meeting.
The aim of this symposium is again to bring together a unique community of clinical scientists and researchers and to discuss the most recent findings in basic research and results of clinical studies and network with the top international experts in these fields.
The scientific program will start on Sunday, February 20, 2022 with a main focus on basic research while the following days will concentrate on translational research and clinical studies. You are cordially invited to use this forum to become updated on recent developments in the complex field of leukemia research and therapy. Satellite Symposia and Meet-the-Expert Sessions will deliver further chances to discuss advances and perspectives of basic science and treatment strategies.
Share your research by submitting an abstract for the poster and the best of free contributions sessions. Join us as a Sponsor or Exhibitor and benefit from maximum visibility and exposure to a broad audience.
To minimize the infection risk for all on-site participants the organizers will constantly assess the risks to reduce COVID-19 transmission and will keep you informed and updated about the latest coronavirus (COVID-19) regulations and guidance to follow. All relevant information on testing, tracking and tracing can be found at www.acute-.leukemias.de under COVID-19 Safety Measures.
You can be certain that your protection and safety are our greatest concerns.
We therefore look forward to welcoming as many on-site participants as possible in Munich by simultaneously reaching out to a wider and more international audience than ever before.
